Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...

New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced ...

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...

Fabhalta ® (iptacopan capsules) is an oral Factor B inhibitor indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) to reduce proteinuria. 1 Phase III APPEAR-C3G ...

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a highly selective oral BTK inhibitor, was ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...